ProShare Advisors’s Enzo Biochem, Inc. ENZ Stock Holding History

ProShare Advisors’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-11,869	Closed	-$41K	–	2414
2021 Q1	$41K	Buy	+11,869	New	+$36.9K	﹤0.01%	2235
2014 Q4	–	Sell	-13,572	Closed	-$70K	–	2139
2014 Q3	$70K	Sell	13,572 -3,080	-18%	-$16.4K	﹤0.01%	2224
2014 Q2	$87K	Buy	+16,652	New	+$72K	﹤0.01%	2389

Other funds holding ENZ

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EGA

Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCA

VIEX Capital Advisors Sunny Isles Beach, Florida $30.9M AUM 55.48% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ProShare Advisors's ENZ Position: Q2 2021 in Review

ProShare Advisors sold out of Enzo Biochem, Inc. (ENZ) in Q2 2021, closing a stake of 11,869 shares — an estimated $41K sold.

ProShare Advisors first reported a position in ENZ in Q2 2014 and held it in 3 quarters. The position peaked at $87K in Q2 2014. 72 funds tracked by Wall St. Rank hold ENZ as of Q2 2021.

ProShare Advisors reported no remaining Enzo Biochem, Inc. position as of Q2 2021 after selling out during the quarter.
ProShare Advisors sold 11,869 Enzo Biochem, Inc. shares in Q2 2021, an estimated $41K.
ProShare Advisors first reported a position in Enzo Biochem, Inc. in Q2 2014 and held it in 3 quarters.
ProShare Advisors's Enzo Biochem, Inc. position peaked at $87K in Q2 2014.
72 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2021.

Based on ProShare Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.